Endoscopic sleeve gastroplasty (ESG), a nonsurgical weight loss procedure, is more cost-effective over a 5-year period than using semaglutide, the active ingredient in Ozempic, Wegovy, and other weight loss drugs, a new study shows.
April 12, 2024 – Endoscopic sleeve gastroplasty , a nonsurgical weight loss procedure, is more cost-effective over a 5-year period than using semaglutide, the active ingredient in Ozempic, Wegovy, and other weight loss drugs, a study says.
Over 1 year, ESG was not as cost-effective as semaglutide, the study said. After that, things changed. Overall, “ESG was found to be a cost-effective strategy, offering greater weight loss and cost savings. The annual cost of semaglutide would need to be reduced 3-fold, from $13,618 to $3,591, for it to be a cost-competitive alternative," the researchers wrote.
American Society for Metabolic and Bariatric Surgery, whose physician members perform the gastric sleeve and other weight loss procedures. “And if you stop them, you have significant weight regain. Patients after surgery can regain some weight, but generally not all the weight from before.”
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Woman Loses 150 Lbs With Gastric Sleeve Surgery, High-Protein DietStephanie Thurrott is a writer who covers mental health, personal growth, wellness, family, food and personal finance, and dabbles in just about any other topic that grabs her attention. When she's not writing, look for her out walking her dog or riding her bike in Pennsylvania's Lehigh Valley.
Read more »
FDA Expands Approval of Fam-Trastuzumab-Deruxtecan-Nxki for HER2-Positive Gastric CancerThe US Food and Drug Administration (FDA) has expanded the approval of fam-trastuzumab–deruxtecan-nxki (Enhertu; AstraZeneca and Daiichi Sankyo, Inc) to adults with unresectable or metastatic as well as adults with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma who had received a prior trastuzumab-based regimen. This approval provides a new treatment option for patients with limited options.
Read more »
Combo Therapy Prolongs Survival in Patients With Gastric CancerThe overall survival advantage held regardless of PD-L1 status in patients receiving the first-line combination of cadonilimab and standard chemotherapy.
Read more »
Combination of Cadonilimab and Chemotherapy Improves Survival in Gastric Cancer PatientsA new study shows that the combination of cadonilimab and standard chemotherapy provides a survival advantage for patients with advanced gastric cancer. The treatment options for these patients are currently limited.
Read more »
This Cap Sleeve Shirt Is My New Go-To for Running ErrandsThis casual cap sleeve shirt has become my favorite go-to shirt for running errands in. Get the details here!
Read more »
Rangers join MLB's uniform patch club, adding sponsor to sleeveThe Rangers are quite familiar with Energy Transfer, which already has signage in Globe Life Field. Rangers managing partner and majority owner Ray Davis co-fou...
Read more »